Moreover, the 36-month beta value for CLOV is 1.92. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CLOV is 377.72M and currently, short sellers hold a 4.22% of that float. On January 13, 2025, CLOV’s average trading volume was 6.18M shares.
CLOV) stock’s latest price update
The stock of Clover Health Investments Corp (NASDAQ: CLOV) has increased by 5.08 when compared to last closing price of 3.64. Despite this, the company has experienced a 16.26% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-13 that WILMINGTON, Del., Jan. 13, 2025 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced a 27% year-over-year growth of its Medicare Advantage (MA) membership during the most recent Annual Election Period (AEP). The Company enters 2025 with over 100,000 members, approximately 95% of whom are enrolled in Clover’s flagship 4-Star PPO plan.
CLOV’s Market Performance
Clover Health Investments Corp (CLOV) has experienced a 16.26% rise in stock performance for the past week, with a 20.66% rise in the past month, and a -3.16% drop in the past quarter. The volatility ratio for the week is 7.04%, and the volatility levels for the past 30 days are at 5.55% for CLOV. The simple moving average for the last 20 days is 16.11% for CLOV stock, with a simple moving average of 67.09% for the last 200 days.
Analysts’ Opinion of CLOV
Many brokerage firms have already submitted their reports for CLOV stocks, with Craig Hallum repeating the rating for CLOV by listing it as a “Buy.” The predicted price for CLOV in the upcoming period, according to Craig Hallum is $6 based on the research report published on December 17, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see CLOV reach a price target of $4. The rating they have provided for CLOV stocks is “Neutral” according to the report published on October 07th, 2024.
Cowen gave a rating of “Market Perform” to CLOV, setting the target price at $3 in the report published on February 02nd of the previous year.
CLOV Trading at 11.72% from the 50-Day Moving Average
After a stumble in the market that brought CLOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.79% of loss for the given period.
Volatility was left at 5.55%, however, over the last 30 days, the volatility rate increased by 7.04%, as shares surge +25.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.70% lower at present.
During the last 5 trading sessions, CLOV rose by +18.54%, which changed the moving average for the period of 200-days by +399.55% in comparison to the 20-day moving average, which settled at $3.30. In addition, Clover Health Investments Corp saw 21.43% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLOV starting from Garipalli Vivek, who purchase 531,700 shares at the price of $1.88 back on Aug 09 ’24. After this action, Garipalli Vivek now owns 1,409,267 shares of Clover Health Investments Corp, valued at $999,596 using the latest closing price.
Garipalli Vivek, the Director of Clover Health Investments Corp, purchase 877,567 shares at $1.14 during a trade that took place back on Jun 17 ’24, which means that Garipalli Vivek is holding 877,567 shares at $1,000,426 based on the most recent closing price.
Stock Fundamentals for CLOV
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.34 for the gross margin
The net margin for Clover Health Investments Corp stands at -0.06. The total capital return value is set at -0.24. Equity return is now at value -28.69, with -11.12 for asset returns.
Currently, EBITDA for the company is -210.84 million with net debt to EBITDA at 3.07. When we switch over and look at the enterprise to sales, we see a ratio of 1.05. The receivables turnover for the company is 21.02for trailing twelve months and the total asset turnover is 2.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.55.
Conclusion
To wrap up, the performance of Clover Health Investments Corp (CLOV) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
